For women at risk of diabetes, cardiovascular disease, metabolic syndrome, or obesity-related illness, these medications may meaningfully improve quality of life and long-term health
Danuglipron is an oral, non-peptide GLP-1 receptor agonist with a pharmacological mechanism that predominantly activates the G protein rather than -arrestin
Warrilow A, Turner M, Naumovski N, Somerset S (2023) Role of cholecystokinin in satiation: a systematic review and meta-analysis
Trial protocols typically include clear guidance on adverse event reporting, and GI symptoms even if seemingly minor should be documented accurately to contribute to the drug's safety profile
Constipation is also common, reported in around 24% of users across clinical trial populations
However, it is important to emphasize that glycine 50 mg/mL injection is not a commercially marketed drug for any specific indication